Sharyn Baker
Title
Cited by
Cited by
Year
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ...
The Lancet 364 (9440), 1127-1134, 2004
18632004
American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: Update 2003
DG Pfister, DH Johnson, CG Azzoli, W Sause, TJ Smith, S Baker Jr, J Olak, ...
Journal of Clinical Oncology 22 (2), 330-353, 2004
18232004
American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer
CG Azzoli, S Baker Jr, S Temin, W Pao, T Aliff, J Brahmer, DH Johnson, ...
Journal of clinical oncology 27 (36), 6251, 2009
9132009
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
BMK Biller, AB Grossman, PM Stewart, S Melmed, X Bertagna, J Bertherat, ...
The Journal of Clinical Endocrinology & Metabolism 93 (7), 2454-2462, 2008
8902008
CREBBP mutations in relapsed acute lymphoblastic leukaemia
CG Mullighan, J Zhang, LH Kasper, S Lerach, D Payne-Turner, ...
Nature 471 (7337), 235-239, 2011
5542011
The genomic landscape of hypodiploid acute lymphoblastic leukemia
L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, ...
Nature genetics 45 (3), 242-252, 2013
5502013
Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
American Society of Clinical Oncology
Journal of Clinical Oncology 15, 2996-3018, 1997
4821997
Does inequality in self-assessed health predict inequality in survival by income? Evidence from Swedish data
E Van Doorslaer, UG Gerdtham
Social science & medicine 57 (9), 1621-1629, 2003
478*2003
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
GA Masters, S Temin, CG Azzoli, G Giaccone, S Baker Jr, JR Brahmer, ...
Journal of Clinical Oncology 33 (30), 3488, 2015
4262015
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ...
Journal of Clinical Oncology, 2017
3972017
2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer
CG Azzoli, S Temin, G Giaccone
Journal of oncology practice 8 (1), 63-66, 2012
3892012
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
ML Amador, D Oppenheimer, S Perea, A Maitra, G Cusati, ...
Cancer Research 64 (24), 9139-9143, 2004
3032004
Irinotecan pathway genotype analysis to predict pharmacokinetics
RHJ Mathijssen, S Marsh, MO Karlsson, R Xie, SD Baker, J Verweij, ...
Clinical cancer research 9 (9), 3246-3253, 2003
3022003
Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy 1 Supported by Eli Lilly and Company. 1
C Niyikiza, SD Baker, DE Seitz, JM Walling, K Nelson, JJ Rusthoven, ...
Molecular cancer therapeutics 1 (7), 545-552, 2002
3022002
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
J Li, M Zhao, P He, M Hidalgo, SD Baker
Clinical Cancer Research 13 (12), 3731-3737, 2007
2912007
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
J Gilbert, SD Baker, MK Bowling, L Grochow, WD Figg, Y Zabelina, ...
Clinical Cancer Research 7 (8), 2292-2300, 2001
2862001
Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001
SD Baker, J Verweij, EK Rowinsky, RC Donehower, JHM Schellens, ...
Journal of the National Cancer Institute 94 (24), 1883-1888, 2002
2802002
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
G Cusatis, V Gregorc, J Li, A Spreafico, RG Ingersoll, J Verweij, ...
Journal of the National Cancer Institute 98 (23), 1739-1742, 2006
2542006
Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial
K Tanabe, PW Serruys, M Degertekin, E Grube, G Guagliumi, W Urbaszek, ...
Circulation 111 (7), 900-905, 2005
2522005
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
SD Baker, M Wirth, P Statkevich, P Reidenberg, K Alton, SE Sartorius, ...
Clinical Cancer Research 5 (2), 309-317, 1999
2421999
The system can't perform the operation now. Try again later.
Articles 1–20